Deals this week: Ascend Therapeutics US, Tyme Technologies, Axsome Therapeutics

23 March 2017 (Last Updated March 23rd, 2017 18:30)

Ascend Therapeutics US will be the exclusive seller and marketer of Aevum Life Science’s Protiva Pregnancy and Protiva New Mom / Recover products across the US, under an agreement signed between the two companies.

Ascend Therapeutics US will be the exclusive seller and marketer of Aevum Life Science's Protiva Pregnancy and Protiva New Mom / Recover products across the US, under an agreement signed between the two companies.

The products are useful for improving quality of life for women during pregnancy and post-delivery.

Canadian biopharmaceutical company Aeterna Zentaris intends to issue shares of its common stock in order to raise $50m in gross proceeds.

The proceeds are intended to be used for general corporate purposes.

Tyme Technologies has raised $8.15m through the private placement of 3.1 million shares to a group of private investors.

The proceeds are intended to be used for initiating Phase II clinical trial in pancreatic cancer and build out its operating structure.

"Tyme Technologies has raised $8.15m through the private placement of 3.1 million shares to a group of private investors."

Based in the US, the company is focused on cancer therapeutics.

US-based biopharmaceutical company Axsome Therapeutics intends to offer shares of its common stock to public through underwriters, who will have a 30-day option to purchase up to an additional 15% of the shares.

The proceeds are intended to fund the company’s ongoing clinical trials, and for working capital and general corporate purposes. The remaining funds will be invested in short-term, investment-grade, interest-bearing instruments and US government securities.

La Jolla Pharmaceutical Company, also a biopharmaceutical company based in the US, intends to raise $100m through a similar offering.

The proceeds are intended to be used for general corporate purposes.